| Literature DB >> 35969647 |
Maylis Douine1,2,3, Timothée Bonifay1, Yann Lambert1, Louise Mutricy1, Muriel Suzanne Galindo1, Audrey Godin1, Pascale Bourhy4, Mathieu Picardeau4, Mona Saout2, Magalie Demar2,5, Alice Sanna1, Emilie Mosnier6, Romain Blaizot2,7, Pierre Couppié2,7, Mathieu Nacher1,2,3, Antoine Adenis1,2,3, Martha Suarez-Mutis8, Stephen Vreden9, Loïc Epelboin1,2,10, Roxane Schaub1,2.
Abstract
BACKGROUND: Most emerging pathogens are zoonoses and have a wildlife origin. Anthropization and disruption of ecosystems favor the crossing of inter-species barriers. We hypothesize that the marginalized population of undocumented goldminers in the Amazon is at risk of acquiring zoonoses.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35969647 PMCID: PMC9410546 DOI: 10.1371/journal.pntd.0010326
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Diseases studied with their ecology, epidemiology, public health issue in the Amazon and assessment method in this study.
| Yellow Fever | Q Fever | Leptospirosis | Leishmaniasis | ||
|---|---|---|---|---|---|
|
| Yellow fever virus |
|
| ||
|
| |||||
|
| |||||
|
|
| Non-human primates | Unclear | Rodents and many mammals described as carriers of | • |
| • | |||||
|
| Vector-borne through | Probable inhalation of contaminated aerosols | Contact of mucous membranes or injured skin with water and soil contaminated with urine of reservoir animals | Vector-borne through | |
|
| Risk of epidemic in French Guiana due to the proximity of gold miners and non-human primates in the forest and the presence of the vectors if low vaccination coverage | Better understand the mode of transmission and the reservoir by looking at whether people living in constant contact with biodiversity are more affected | • Evaluation of the morbidity linked to leptospirosis among this exposed population | • Pathology complained as a major problem by the concerned population [ | |
| • Evaluation of the risk of misdiagnosis of febrile illnesses in this highly malaria-exposed population | • Increased proportion of | ||||
| • Rumors of intense circulation of black market anti-leishmanial drugs known for potentially severe adverse effects | |||||
|
| • vaccination coverage (declared) | Seroprevalence of Q-fever | • Seroprevalence of leptospirosis | • prevalence of active leishmaniasis lesion | |
| • proportion of the study population being protected by seroneutralizing antibodies | • Identification of the different serovars | • proportion of different | |||
| • use of anti-leishmaniasis drugs during the previous year | |||||
|
|
| • questionnaire about previous yellow fever immunization | • questionnaire about use of antileishmaniosis treatment during the last year | ||
|
| • medical examination: active lesions of leishmaniasis (specific training of the investigating physician in the dermatology department of the Cayenne hospital) | ||||
|
| • Seroneutralizing antibody test | • Phase I and II IgG using Enzyme-Linked Immunosorbent Assay (ELISA) | • Microscopic Agglutination Test (MAT) | • Swab of the bottom of the lesion in case of active lesion for PCR | |
| • For phase I antibodies, the sample was considered positive when the serum OD was >10% above the OD cut-off value. For phase II, antibody activities in IU/mL were calculated following maufacturer’s guidelines using a standard curve which was supplied in the kit. | • A positive case was defined as having a positive MAT with a title > = 1/50 (Goris and Hartskeerl 2014) | ||||
| • A seropositive case was defined as having IgG Phase I positive and/or IgG PhII positive | • Description of serovars with titer > = 1/800 due to numerous cross-reactions | ||||
| • 380 persons included on the Maroni river in 2019 (376 samples analyzed | • 380 persons included on the Maroni river in 2019 (380 samples analyzed) | • 421 persons included on the Maroni river in 2015 (412 samples analyzed) | • 380 persons included on the Maroni river in 2019 | ||
| • 380 persons included on the Maroni river in 2019 (378 samples analyzed | |||||
* some of the samples were not full enough to make the aliquots needed for these analyses, resulting in a different number of samples than the number of people included
Fig 1Map of inclusion sites at the Suriname-French Guiana border (map background from dmap https://d-maps.com/pays.php?num_pay=5267&lang=fr).
Characteristic of the study population of 380 clandestine gold miners working in French Guiana, 2019.
| n (%) | |||
|---|---|---|---|
|
| |||
|
| Median age [IQR] | 39 [31–48] | |
| < = 29 yo | 80 (21.1) | ||
| 30–44 yo | 168 (44.2) | ||
| > = 45 yo | 132 (34.7) | ||
|
| Women | 102 (26.8) | |
| Men | 278 (73.2) | ||
|
| None or primary | 130 (34.3) | |
| Secondary | 239 (63.1) | ||
| Superior | 10 (2.6) | ||
|
| Brazil | 363 (95.5) | |
| Other than Brazil | 17 (4.5) | ||
|
| |||
|
| ≤ 5 years | 118 (31.1) | |
| 6–10 years | 87 (22.9) | ||
| 11–15 years | 55 (14.6) | ||
| > 15 years | 119 (31.4) | ||
|
| < = 6 months | 231 (61.8) | |
| >6months | 143 (38.2) | ||
|
| <2 hours | 29 (7.8) | |
| 2 hours to half day | 117 (31.4) | ||
| 1 day | 92 (24.6) | ||
| > 1 day | 98 (26.3) | ||
| Do not know | 37 (9.9) | ||
|
| Gold miner | 230 (60.4) | |
| Machine operator | 6 (1.6) | ||
| Sex worker | 1 (0.3) | ||
| Carrier | 16 (4.2) | ||
| Bar owner | 4 (1.1) | ||
| Store owner | 3 (0.8) | ||
| Housekeeper/cook | 54 (14.2) | ||
| Mobile salesman | 52 (13.7) | ||
| Unemployed | 3 (0.8) | ||
| Transporter | 1 (0.3) | ||
| Other | 7 (1.8) | ||
| Do not know | 3 (0.8) | ||
|
| Non-mobile activity | 305 (80.2) | |
| Mobile activity | 72 (19.0) | ||
| Do not know | 3 (0.8) | ||
|
| Median [IQR] | 3 [ | |
* main activity on the mine itself as gold miner, cook…
** main activity involving great mobility as a transporter, dugout driver…
Serovars, medical context ang gold mining activity of the six participants with antibodies titers for leptospirosis > = 1/800, French Guiana, 2015 and 2019.
| Date | Serovar tested | Titer value | Patient | Gold mining activity | Medical context at inclusion |
|---|---|---|---|---|---|
|
|
| 1/800 | 36-year-old man | gold miner in Eau-Claire region, working for 1 year in gold mining | No fever or other clinical signs, malaria RDT and PCR negative |
|
| 1/800 | 31-year-old man | gold miner in Mana region, working for 2 years in gold mining | No fever or other clinical signs, malaria RDT and PCR negative | |
|
| 1/800 | 28-year-old man | dugout driver in Sophia region, working for 6 months in gold mining | Apyretic, asymptomatic, but RDT positive for | |
|
| 1/800 | 27-year-old man | gold miner in Mana region, working for 10 years in gold mining | No fever or other clinical signs, malaria RDT and PCR negative | |
|
| 1/800 | 31-year-old man | gold miner in Eau-Claire region, working for 3 years in gold mining | Presented fever, no other symptoms recorded, positive RDT for | |
|
|
| 1/800 | 29-year-old man | carrier in Eau-Claire region, working for 10 years in gold mining | Declared having had fever and headache 7 days before, self-medicated with Artemether-Lumefantrine (4 tablets on three occasions), no longer had headache or fever at the time of inclusion but had digestive disorders. Negative RDT and PCR for malaria, was referred to the health center for further investigations (did not go) |
* gold miner means person who worked directly on the mine and not for support (logistic, transport, mechanic…)
Factors associated with positive leptospirosis serology among the population of illegal gold miners included in the 2015 and 2019 studies (univariate and multivariate analysis).
| 2015 | 2019 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | OR | p | AOR | n (%) | OR | p | AOR | |||
|
|
|
|
|
|
|
|
|
| ||
|
|
| < = 29 yo | 24 (27.3) | / | 0.300 | / | 24 (31.2) | / | 0.770 | / |
| 30–44 yo | 61 (29.5) | 1.1 [0.6–1.9] | 1.2 [0.7–2.3] | 44 (26.7) | 0.8 [0.4–1.5] | 0.7 [0.4–1.4] | ||||
| > = 45 yo | 41 (36.6) | 1.5 [0.8–2.8] | 1.7 [0.8–3.3] | 36 (28.1) | 0.9 [4.6–1.6] | 0.7 [0.4–1.3] | ||||
|
|
| Women | 24 (20.2) | / |
| / | 13 (13.0) | / |
| / |
| Men | 102 (35.4) | 2.2 [1.3–3.6] | 2.5 [1.4–4.5] | 91 (33.7) | 3.4 [1.8–6.4] | 3.3 [1.7–6.5] | ||||
|
|
| None or primary | 66 (33.7) | / | 0.254 |
| 38 (30.2) | / | 0.545 |
|
| Secondary or superior | 60 (28.4) | 0.8 [0.5–1.2] |
| 66 (27.2) | 0.9 [0.5–1.4] |
| ||||
|
|
| Other than Brazil | 6 (24.0) | / | 0.427 |
| 1 (5.9) | / |
|
|
| Brazil | 120 (31.4] | 1.5 [0.6–3.7] |
| 103 (29.2) | 6.6 [0.9–50.4] |
| ||||
|
|
|
|
|
|
|
|
|
| ||
|
|
| < = 10 years | 67 (27.9) | / |
|
| 54 (27.0) | / | 0.671 |
|
| >10 years | 59 (35.3) | 1.0 [1.0–1.0] |
| 49 (29.0) | 1.0 [1.0–1.0] |
| ||||
|
|
| < = 6 months | 61 (29.8) | / | 0.679 |
| 53 (23.5) | / |
| / |
|
| > 6 months | 63 (31.7) | 1.0 [1.0–1.0] |
| 49 35.5] | 1.0 [1.0–1.1] | 1.0 [1.0–1.1] | |||
|
|
| < = 1 day | 38 (27.7) | / | 0.373 |
| 44 (30.8) | / | 0.411 | |
| > 1 day | 78 (32.1) | 1.2 [0.8–2.0] |
| 49 (26.6) | 0.8 [0.5–1.3] |
| ||||
|
|
| Other than gold miners | 55 (26.7) | / |
|
| 28 (18.9) | / |
|
|
|
| Gold miner | 71 (35.3) | 1.5 [1.0–2.3] |
| 76 (34.2) | 2.2 [1.4–3.7] |
| |||
|
|
| Pits | 5 (15.2) | / |
|
| 22 (31.4) | / | 0.511 |
|
|
| Alluvionnary | 59 (30.0) | 2.4 [0.9–6.5] |
| 67 (27.7) | 0.8 [0.5–1.5] |
| |||
|
| Both | 56 (35.2) | 3.0 [1.1–8.3] |
| 9 (21.4) | 0.6 [0.2–1.5] |
| |||
|
|
| Day | 103 (32.4) | / |
|
| 76 (27.7) | / | 0.638 |
|
|
| Night or both | 22 (25.0) | 0.7 [0.4–1.2] |
| 27 (30.3) | 1.1 [0.7–1.9] |
| |||
|
|
| North-West | 40 (38.8) | / |
|
| 45 (32.1) | / | 0.493 |
|
|
| South-West | 75 (29.0) | 0.6 [0.4–1.0] |
| 55 (26.3) | 0.8 [0.5–1.2] |
| |||
|
| South-East | 3 (17.6) | 0.3 [0.1–1.2] |
| 1 (33.3) | 1.1 [0.1–11.9] |
| |||
|
| North-East | 1 (50.0) | 1.6 [0.9–25.9] |
| 0 (0) | / |
|
| ||
|
|
| < = 3 | 75 (29.8) | / | 0.506 |
| 66 (24.9) | / |
| / |
|
| >3 | 51 (32.9) | 1.0 [1.0–1.0] |
| 38 (36.2) | 1.0 [1.0–1.0] | 1.0 [1.0–1.1] | |||
* Odds-Ratio
** Adjusted Odds-Ratio after logistical regression
Fig 2Three cutaneous leishmaniasis lesions on a gold miner included in the 2019 study.
Use of anti-leishmanial treatment in the previous year among gold miners included in the 2019 study along the Maroni border.
| Active lesion of leishmaniasis | No active lesion of leishmaniasis | ||
|---|---|---|---|
|
| 9 (2.4) | 371 (97.6%) | |
|
| |||
|
| yes | 5 (55.6) | 17 (4.6) |
|
| no | 4 (44.4) | 345 (93.0) |
|
| missing data | 0 (0) | 9 (2.4) |
|
| |||
|
| meglumine antimoniate | 0 | 1 |
|
| pentamidine | 5 | 16 |
|
| |||
|
| mining site | 3 (60.0) | 8 (47.1) |
|
| health care facility | 1 (20.0) | 6 (35.3) |
|
| both | 1 (20.0) | 2 (11.7) |
|
| do not know | 0 (0) | 1 (5.9) |
|
| |||
|
| 1 | 2 | 3 |
|
| 2 | 4 | |
|
| 3 | 2 | 3 |
|
| 4 | 1 | 3 |
|
| 5 | 1 | |
|
| 6 | 1 | |
|
| not specified | 2 | |